Literature DB >> 17376389

Tim protein structures reveal a unique face for ligand binding.

Ana C Anderson1, Sheng Xiao, Vijay K Kuchroo.   

Abstract

Tim molecules regulate T cell responses; however, the molecular basis of their ligand recognition remains largely unknown. In this issue of Immunity, Santiago et al. (2007) and Cao et al. (2007) report the crystal structures of several Tims and provide insights into the structure-function relationship of these molecules.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17376389     DOI: 10.1016/j.immuni.2007.03.004

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  7 in total

1.  Effect of the use of Galectin-9 and blockade of TIM-3 receptor in the latent cellular reservoir of HIV-1.

Authors:  Marta Sanz; Nadia Madrid-Elena; Sergio Serrano-Villar; Alejandro Vallejo; Carolina Gutiérrez; Santiago Moreno
Journal:  J Virol       Date:  2020-12-23       Impact factor: 5.103

2.  Antagonism of TIM-1 blocks the development of disease in a humanized mouse model of allergic asthma.

Authors:  Sanchaita Sriwal Sonar; Yen-Ming Hsu; Melanie Lynn Conrad; Gerard R Majeau; Ayse Kilic; Ellen Garber; Yan Gao; Chioma Nwankwo; Gundi Willer; Jan C Dudda; Hellen Kim; Véronique Bailly; Axel Pagenstecher; Paul D Rennert; Harald Renz
Journal:  J Clin Invest       Date:  2010-07-12       Impact factor: 14.808

3.  Virion-associated phosphatidylethanolamine promotes TIM1-mediated infection by Ebola, dengue, and West Nile viruses.

Authors:  Audrey Stéphanie Richard; Adam Zhang; Sun-Jin Park; Michael Farzan; Min Zong; Hyeryun Choe
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-02       Impact factor: 11.205

Review 4.  TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action.

Authors:  Wenwen Du; Min Yang; Abbey Turner; Chunling Xu; Robert L Ferris; Jianan Huang; Lawrence P Kane; Binfeng Lu
Journal:  Int J Mol Sci       Date:  2017-03-16       Impact factor: 5.923

Review 5.  TIM-3, a promising target for cancer immunotherapy.

Authors:  Yayi He; Jie Cao; Chao Zhao; Xuefei Li; Caicun Zhou; Fred R Hirsch
Journal:  Onco Targets Ther       Date:  2018-10-16       Impact factor: 4.147

6.  Phosphatidylserine-Induced Conformational Modulation of Immune Cell Exhaustion-Associated Receptor TIM3.

Authors:  Jeffrey K Weber; Ruhong Zhou
Journal:  Sci Rep       Date:  2017-10-19       Impact factor: 4.379

7.  Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease.

Authors:  Andrew S Flies; Nicholas B Blackburn; Alan Bruce Lyons; John D Hayball; Gregory M Woods
Journal:  Front Immunol       Date:  2017-05-03       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.